bioRxiv Science⌕ Search

Biology subjects

Marzook, H.

Publications and source records attributed to Marzook, H..

2 recordsLinked to original sources

GSK-3alpha-BNIP3 axis promotes mitophagy in human cardiomyocytes under hypoxia

Dysregulated autophagy/mitophagy is one of the major causes of cardiac injury in ischemic conditions. Glycogen synthase kinase-3alpha (GSK-3) has been shown to play a crucial role in the pathophysiology of cardiac diseases. However, the precise role of GSK-3 in cardiac mitophagy remains unknown. Herein, we investigated the role of GSK-3 in cardiac mitophagy by employing AC16 human cardiomyocytes under the condition of acute hypoxia. We observed that the gain-of-GSK-3 function profoundly induced mitophagy in the AC16 cardiomyocytes post-hypoxia. Moreover, GSK-3 overexpression led to increased ROS generation and mitochondrial dysfunction in cardiomyocytes, accompanied by enhanced mitophagy displayed by increased mt-mKeima intensity under hypoxia. Mechanistically, we identified that GSK-3 promotes mitophagy through upregulation of BNIP3, caused by GSK-3-mediated increase in expression of HIF-1 and FOXO3a in cardiomyocytes post-hypoxia. Moreover, GSK-3 displayed a physical interaction with BNIP3 and, inhibited PINK1 and Parkin recruitment to mitochondria was observed specifically under hypoxia. Taken together, we identified a novel mechanism of mitophagy in human cardiomyocytes. GSK-3 promotes mitochondrial dysfunction and regulates FOXO3a -mediated BNIP3 overexpression in cardiomyocytes to facilitate mitophagy following hypoxia. An interaction between GSK-3 and BNIP3 suggests a role of GSK-3 in BNIP3 recruitment to the mitochondrial membrane where it enhances mitophagy in stressed cardiomyocytes independent of the PINK1/Parkin.

cell biology↗

Natural compound screening predicts novel GSK-3 isoform-specific inhibitors

Glycogen synthase kinase-3 (GSK-3) plays important roles in the pathogenesis of cardiovascular, metabolic, neurological disorders and cancer. Isoform-specific loss of either GSK-3 or GSK-3{beta} often provides cytoprotective effects under such clinical conditions. However, available synthetic small molecule inhibitors are relatively non-specific, and their chronic use may lead to adverse effects. Therefore, screening for natural compound inhibitors to identify the isoform-specific inhibitors may provide improved clinical utility. Here, we screened 70 natural compounds to identify novel natural GSK-3 inhibitors employing comprehensive in silico and biochemical approaches. Molecular docking and pharmacokinetics analysis identified two natural compounds Psoralidin and Rosmarinic acid as potential GSK-3 inhibitors. Specifically, Psoralidin and Rosmarinic acid exhibited the highest binding affinities for GSK-3 and GSK-3{beta}, respectively. Consistent with in silico findings, the kinase assay-driven IC50 revealed superior inhibitory effects of Psoralidin against GSK-3 (IC50=2.26 {micro}M) vs. GSK-3{beta} (IC50=4.23 {micro}M) while Rosmarinic acid was found to be more potent against GSK-3{beta} (IC50=2.24 {micro}M) than GSK-3 (IC50=5.14 {micro}M). Taken together, these studies show that the identified natural compounds may serve as GSK-3 inhibitors with Psoralidin serving as a better inhibitor for GSK-3 and Rosmarinic for GSK-3{beta} isoform, respectively. Further characterization employing in vitro and preclinical models will be required to test the utility of these compounds as GSK-3 inhibitors for cardiometabolic and neurological disorders and cancers. HighlightsO_LICurrent GSK-3 inhibitors lack specificity and cause side effects. C_LIO_LIThis study identifies potential GSK-3 isoform-specific natural compounds. C_LIO_LIPsoralidin is likely a better inhibitor for GSK-3 while Rosmarinic for GSK-3{beta}. C_LIO_LIThese natural compounds may be promising future treatments. C_LI

biochemistry↗